Cell-free and concentrated ascites reinfusion therapy (CART) is recognized as a useful treatment to improve the symptoms caused by refractory ascites. Recently, a few clinical studies have reported the effects of CART for malignant ascites, especially in gynecological and gastrointestinal cancers. We report the case of malignant ascites in a patient with malignant pleural mesothelioma (MPM) whose symptoms were relieved by CART. A 59-year-old Japanese male with MPM who had undergone pleural decortication had pleural and peritoneal recurrence. His general status deteriorated as he developed massive ascites due to peritoneal metastases. With the initiation of CART, he recovered well enough to receive cisplatin-based systemic chemotherapy. Repeated use of CART contributed to the maintenance of his good general condition and enabled him to undergo successive systemic chemotherapy, which might have lengthened his life. This is the first report that demonstrates the efficacy of CART for palliative care in a patient with MPM. Our experience indicates that CART should be considered as a treatment option to control refractory malignant ascites regardless of the type of cancer. (J Nippon Med Sch 2017; 84: 231 236) 
Introduction
Cell-free and concentrated ascites reinfusion therapy (CART) is a type of apheresis therapy, which was first reported in 1960 1 . CART is carried out in four steps: 1) ascites paracentesis; 2) removal of cell components from the fluid, including cancer cells, by filtration with a plasma-separating filter; 3) concentration of the fluid by the removal of isotonic salt and water by filtration with a dialysis filter; and 4) intravenous reinfusion of the final fluid product 2 . CART has been applied to treat refractory ascites in patients with conditions such as liver cirrhosis, congestive heart failure, nephrotic syndrome, and malignancy.
The number of reports elucidating the effects of CART for malignant ascites has increased, especially in gynecological 3 5 and gastrointestinal cancers 5 8 . However, little is known about the importance of CART in other types of cancer. We report the case of a patient with malignant pleural mesothelioma (MPM) suffering from malignant ascites, whose symptoms were relieved by CART. Repeated use of CART, together with systemic chemotherapy, may have contributed to a longer survival.
Case
A 59-year-old Japanese male with MPM was admitted to our hospital because of massive ascites. He was a former smoker, and he had worked for fourteen years demolishing houses, with occupational exposure to asbestos. About 1.5 years prior to admission, he had initially been diagnosed with malignant epithelioid mesothelioma on cell block samples from a pleural effusion. He had undergone two cycles of neoadjuvant chemotherapy with cisplatin (CDDP) (75 mg/m 2 on day 1) and pemetrexed (PEM) (500 mg/m 2 on day 1), followed by pleural decortication of the right pleura. Immunohistochemical staining of surgically-resected pleural samples had shown that Fig. 2A) , pleural dissemination (Fig. 2B) , peritoneal dissemination, and massive ascites ( Fig. 2C and D) . Although the result of the ascitic fluid cytology was re- The clinical course after hospitalization is shown in One more CART was performed in the outpatient department. In the second CART, the amount of collected as- Three months after the second cycle of chemotherapy, CT revealed that pleural dissemination had slightly increased, but the ascites had disappeared ( Fig. 4A and B) .
The serum albumin level had returned to normal. He was determined to restart treatment. Although the disease progression had arrested to some extent by continuing chemotherapy, his ascites gradually increased again.
CART was reintroduced for palliative care, but after administration of an additional 6 cycles of chemotherapy, we continued to provide best supportive care. CART was repeated for symptom relief, and he was able to spend the rest of his life mostly at home. He died at home 3 months after the last course of chemotherapy. because the amount of fluid that can safely be drained each time is limited 12 14 . Repeated paracenteses may lead to loss of protein 15, 16 . Furthermore, a decrease in circulating plasma volume due to draining large amounts of ascitic fluid may cause renal dysfunction 12, 14 . Therefore, the administration of albumin is often required. In CART, cellular components are removed from the original ascites, the collected fluid is concentrated by removing water, and it is then reinfused intravenously into the patient. Hence, large amounts of ascites can be safely While this is a useful treatment option to control malignant pleural effusion, adhesion therapy is not done for ascites. It is relatively rare for thoracic neoplasms to cause ascites; accordingly, little is known about CART in the field of thoracic oncology. It is important for this procedure, which can be performed on an outpatient basis or even at home, to be considered for patients with thoracic neoplasms suffering from ascites.
Discussion
In conclusion, CART effectively relieved symptoms due to massive ascites in a patient with MPM and repeated use of CART, together with systemic chemotherapy, may contribute to prolonged survival in such patients. This is the first report demonstrating the efficacy of CART for palliative care in a patient with MPM. Our experience indicates that CART should be considered as a very effective treatment option to control malignant refractory ascites, regardless of the type of cancer.
